Asthma management across the life course: GAN phase I

Professor Eva Morales, Universidad de Murcia, Spain

Global Asthma Network (GAN) Phase I is the first study to provide individual-level data worldwide on asthma medicine use, management plan availability, and disease control in childhood, adolescence, and adulthood. This global report provides a novel insight on the use of medications by individuals with diagnosed asthma, how medicines are used relative to the severity of asthma symptoms, the use of asthma management plans, and factors related to asthma control across the life course in countries with different income economies. Data from 101777 children, 157784 adolescents and 193912 adults from 63 centers in 25 countries have revealed inhaled short-acting β2 agonist (SABA) and inhaled corticoids as the most used medicines, with a significant increasing use as the severity of symptoms increased for all age groups. However, an important proportion of individuals with severe asthma symptoms (44-60%) does not take inhaled corticoids, and this proportion is significantly higher in low country income categories. Contrary to current guidelines, oral SABA and theophylline are used across all age groups and country income categories. Management plans are used by 44-63% of asthmatics worldwide, which increases the probability of using inhaled and oral medicines. Asthma is better controlled in adults in comparison with children and adolescents, and a notable increased trend of poorly controlled asthma in all age groups is observed in less affluent countries. Improving compliance to recommended asthma medicine use and assuring the availability and affordability of quality-assured essential medicines across the life course are urgent needs to mitigate asthma burden, particularly in children and in less affluent settings.


  • García-Marcos L, Chiang C-Y, Asher MI, Marks GB, El Sony A, Masekela R, Bissell K, Ellwood E, Ellwood P, Pearce N, Strachan DP, Mortimer K, Morales E and the Global Asthma Network Phase I Study Group. Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study. Lancet Global Health 2023; 11: e218–28.


GAN gratefully acknowledges funding from the University of Auckland and Wellcome (Grant number 203919/Z/16/Z) as well as sponsorship from AstraZeneca and GlaxoSmithKline that has helped to make the GAN Symposium 2024 possible. We thank the speakers and the organisations they represent for their contributions including securing their own funding to enable their participation. The Symposium programme was developed independently by the GAN Steering Group.

Attention GAN Collaborators

Our network has been targeted by an email scam. If you receive any unusual requests for assistance from any of the steering group members, please ignore it.

These emails are a common scam that has also targeted many other organisations. Please note we will never make any request for financial assistance from our collaborators. If you have any questions please contact us at info@globalasthmanetwork.org